ANDREW F. STEWART, M.D.; JAY L. HOECKER, M.D.; LAWRENCE E. MALLETTE, M.D., Ph.D.; GINO V. SEGRE, M.D.; THOMAS T. AMATRUDA, M.D.; AGNES VIGNERY, D.D.S., Ph.D.
STEWART AF, HOECKER JL, MALLETTE LE, SEGRE GV, AMATRUDA TT, VIGNERY A. Hypercalcemia in Pheochromocytoma: Evidence for a Novel Mechanism. Ann Intern Med. 1985;102:776-779. doi: 10.7326/0003-4819-102-6-776
Download citation file:
Published: Ann Intern Med. 1985;102(6):776-779.
A child with a pheochromocytoma had hypercalcemia but no evidence for excessive parathyroid hormone secretion from the parathyroid glands or the pheochromocytoma. Therapy with the catecholamine synthesis inhibitor metyrosine (alpha-methyltyrosine) reversed the catecholamine excess but had no effect on the hypercalcemia. Adrenalectomy promptly reversed the hypercalcemia. Extracts of the tumor contained a substance(s) that produced both potent in-vitro bone resorption and striking adenylate-cyclase-stimulating activity in renal cortical membranes. This stimulating activity was due to activation of the parathyroid hormone receptor/adenylate cyclase complex but was not due to parathyroid hormone. Our findings document hypercalcemia in association with pheochromocytoma and show that hypercalcemia occurred in the absence of previously proposed mechanisms. We also provide preliminary characterization of the presumed responsible substance(s) and suggest that this substance(s) may be related to that associated with the humoral hypercalcemia of malignancy.
Learn more about subscription options.
Register Now for a free account.
Adrenal Disorders, Endocrine and Metabolism, Fluid and Electrolyte Disorders, Nephrology.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only